Pathios Therapeutics Limited, a UK-based biotech company, announced on Tuesday that it has named Paul G. Higham as its new chief executive officer (CEO).

With more than 20 years of C-level executive biotechnology company experience, Higham has worked as chief executive officer of Valo Therapeutics, and CEO at two other immuno-oncology focused companies, Glycotope, and Immatics Biotechnologies. He has also worked at Ark Therapeutics Group, as vice president, in commercial development at GSK and as general manager of Bayer Pharmaceuticals for Sweden and Denmark.

Higham said: "With an exciting first-in-class therapeutic candidate poised for advancement into first-in-human clinical studies and support from a top-tier investor syndicate of Bristol Myers Squibb, Canaan and Brandon Capital, Pathios is exceptionally well positioned for success. I am delighted to have the opportunity to bring my experience and energy to what is already an exceptional leadership team and help advance the exciting GPR65 antagonist approach at Pathios into much-needed additional therapeutic approaches for patients battling cancer."